Kaya Holdings Reports Q1 2025 Results Amid Shift to Psychedelic Treatments, Faces Financial Challenges

Kaya Holdings, Inc. (OTCBB: KAYS) reported its quarterly results for the three months ended March 31, 2025, maintaining a focus on its transition from cannabis to psychedelic treatments.

Key Financial Metrics:

• Net Sales: $7,052 for Q1 2025 (up from $0 in Q1 2024).
• Gross Profit: $2,082, reflecting sales from new psychedelic operations.
• Total Operating Expenses: $311,620, an increase from $238,830 year-over-year.
• Net Loss: $(1,636,770) for Q1 2025, compared to $(1,084,992) for Q1 2024.
• Cash Position: Increased to $50,718, up from $39,668 at year-end 2024.
• Current Liabilities: $9,660,723, reflecting significant debts and accrued expenses.
• Working Capital Deficiency: $(9,580,900) as of March 31, 2025.

Positive Aspects:

• Transition into psychedelic treatments with the opening of The Sacred Mushroom facility.
• Generated initial revenue from psychedelic operations, signaling a strategic pivot and potential for future growth.
• Cash reserves increased, indicating improved cash management and ability to fund operations temporarily.

Negative Aspects:

• Operating loss widened, with a significant increase in total operating expenses driven primarily by professional fees and salaries related to new operations.
• Significant liabilities, including accrued interest and convertible debts, pose elevated financial risk and dependence on further capital fundraising to survive.
• Discontinued cannabis operations have ceased generating revenues, significantly impacting overall financial performance.

Outlook:

Kaya Holdings is poised at a critical juncture as it navigates the nascent psychedelic treatment space after discontinuing its cannabis retail operations. The company emphasizes the need for additional capital and is exploring equity and debt financing options to stabilize its financial footing and execute on its growth plans.

Investors should monitor further developments regarding The Sacred Mushroom's performance and potential licensing arrangements to gauge operational viability moving forward.